Swiss technology company Neo Medical SA has announced that its entire spine surgery product portfolio has been certified under the European Union's (EU) Medical Device Regulation (MDR) EU 2017/745. This certification confirms that Neo's products meet the highest global quality control standards for medical devices, ensuring the company can continue serving its markets without disruption.

MDR certification marks a significant milestone for Neo, highlighting the strength of its focus on long-term clinical evaluation and its commitment to safety throughout a product’s lifecycle. The new regulatory standards, introduced in 2017, are more stringent than the previous Medical Device Directive (MDD), with increased emphasis on safety, risk management, and comprehensive lifecycle oversight.

Unlike some manufacturers who have withdrawn products from the European market due to the demanding requirements, Neo's entire portfolio remains unaffected. The company sees this certification as a valuable opportunity to expand its market reach and reinforce its dedication to patient safety and product quality.

The MDR transition, which replaces MDD certification for Class III and Class IIb implantable devices by December 2027 and for all other devices by December 2028, requires manufacturers to meet rigorous conditions.

To comply with MDR, medical device manufacturers must:

• Implement a robust quality management system (QMS): Devices must be developed under a QMS that ensures stringent controls across design, manufacturing, and post-market oversight.
• Provide clinical evidence: Manufacturers must demonstrate the safety and efficacy of devices through detailed risk/benefit analysis and clinical data.
• Strengthen regulatory processes: The MDR demands thorough documentation, enhanced risk management processes, post-market performance evaluations, and conformity assessments by Notified Bodies.

This certification secures Neo's market presence in Europe and globally, laying a stable foundation for growth and ongoing technological innovation in spine surgery. The approval confirms Neo's commitment to meeting the 2027 and 2028 deadlines for compliance and to maintaining the highest standards of patient care.

 

 

Source: businesswire.com

Report Abuse